Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 6
Submit an article Journal homepage
450
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

Incidence of thrombosis in relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experience

Megan Melodya Department of Internal Medicine, Mayo Clinic, Jacksonville, FL, USA
,
Sangeetha Gandhib Division of Hematology, Mayo Clinic, Rochester, MN, USA
,
Hollie Saundersa Department of Internal Medicine, Mayo Clinic, Jacksonville, FL, USA
,
Zaid Abdel-Rahmanc Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USA
,
Jacquelyn Hastingsd Department of Critical Care Medicine, Mayo Clinic, Jacksonville, FL, USA
,
Paula Lengerke Diaze Division of Hematology-Oncology and Blood and Marrow Transplantation, Mayo Clinic, Phoenix, AZ, USA
,
Nicole Gannonc Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USA
,
Tuan Truongb Division of Hematology, Mayo Clinic, Rochester, MN, USA
,
Matthew Hathcockb Division of Hematology, Mayo Clinic, Rochester, MN, USA
,
Arushi Khuranab Division of Hematology, Mayo Clinic, Rochester, MN, USA
,
Patrick Johnstonb Division of Hematology, Mayo Clinic, Rochester, MN, USA
,
Stephen Ansellb Division of Hematology, Mayo Clinic, Rochester, MN, USA
,
Nora Bennanib Division of Hematology, Mayo Clinic, Rochester, MN, USAORCID Iconhttps://orcid.org/0000-0001-8358-5953
ORCID Icon,
Jonas Paludob Division of Hematology, Mayo Clinic, Rochester, MN, USAORCID Iconhttps://orcid.org/0000-0002-7350-5531
ORCID Icon,
Jose Villasboas Bisnetob Division of Hematology, Mayo Clinic, Rochester, MN, USAORCID Iconhttps://orcid.org/0000-0002-2907-0809
ORCID Icon,
Yucai Wangb Division of Hematology, Mayo Clinic, Rochester, MN, USA
,
Allison Rosenthale Division of Hematology-Oncology and Blood and Marrow Transplantation, Mayo Clinic, Phoenix, AZ, USA
,
James Foranc Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USA
,
Ernesto Ayalac Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USA
,
Hemant S. Murthyc Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USA
,
Vivek Royc Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USA
,
Januario E. Castroe Division of Hematology-Oncology and Blood and Marrow Transplantation, Mayo Clinic, Phoenix, AZ, USA
,
Yi Linb Division of Hematology, Mayo Clinic, Rochester, MN, USA
&
Mohamed A. Kharfan-Dabajac Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7394-5185
ORCID Icon show all
Pages 1363-1368 | Received 27 Jul 2021, Accepted 11 Jan 2022, Published online: 03 Feb 2022

References

  • Yokoyama K. Thrombosis in lymphoma patients and in myeloma patients. Keio J Med. 2015;64(3):37–43.
  • Mohren M, Markmann I, Jentsch-Ullrich K, et al. Increased risk of thromboembolism in patients with malignant lymphoma: a single-Centre analysis. Br J Cancer. 2005;92(8):1349–1351.
  • Yildiz A, Albayrak M, Pala C, et al. The incidence and risk factors of thrombosis and the need for thromboprophylaxis in lymphoma and leukemia patients: a 9-year single-center experience. J Oncol Pharm Pract. 2020;26(2):386–396.
  • Komrokji RS, Uppal NP, Khorana AA, et al. Venous thromboembolism in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2006;47(6):1029–1033.
  • Feins S, Kong W, Williams EF, et al. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019;94(S1):S3–S9.
  • Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017;377(26):2531–2544.
  • Roex G, Feys T, Beguin Y, et al. Chimeric antigen Receptor-T-Cell therapy for B-Cell hematological malignancies: an update of the pivotal clinical trial data. Pharmaceutics. 2020;12(2):194.
  • Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127(26):3321–3330.
  • Garcia Borrega J, Godel P, Ruger MA, et al. In the eye of the storm: Immune-mediated toxicities associated with CAR-T cell therapy. Hemasphere. 2019;3(2):e191.
  • Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188–195.
  • Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy – assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47–62.
  • Mei H, Jiang H, Wu Y, et al. Neurological toxicities and coagulation disorders in the cytokine release syndrome during CAR-T therapy. Br J Haematol. 2018;181(5):689–692.
  • Wang Y, Qi K, Cheng H, et al. Coagulation disorders after chimeric antigen receptor T cell therapy: Analysis of 100 patients with relapsed and refractory hematologic malignancies. Biol Blood Marrow Transplant. 2020;26(5):865–875.
  • Jiang H, Liu L, Guo T, et al. Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy. Ann Hematol. 2019;98(7):1721–1732.
  • Hashmi H, Mirza AS, Darwin A, et al. Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma. Blood Adv. 2020;4(17):4086–4090.
  • Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625–638.
  • Locke FL, Rossi JM, Neelapu SS, et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020;4(19):4898–4911.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.